ARGNF News and Press, Argen X NV From 10/19/23

2023-10-19 01:20:00 ET Summary Baron Health Care Fund invests in companies engaged in the research, development, production, sale, delivery, or distribution of products and services related to the health care industry. The Fund trailed the Benchmark by 217 basis points this quarte...

VYVGART Ⓡ is the first-and-only neonatal Fc receptor ( FcRn ) blocker authorized for sale in Canada Approval based on the positive Phase 3 ADAPT trial (p<0.0 0 01) showing 68% of VYVGART-treated patients wer...

Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod, compared to intravenous (IV) administration European Commission (EC) decision on marketing authorization applica...

2023-08-31 03:30:52 ET Summary Baker Brothers' 13F portfolio value decreased from $18.38B to $17.28B. The largest five stakes in the portfolio are Seagen, Incyte, BeiGene, ACADIA Pharmaceuticals, and Madrigal Pharmaceuticals, making up around 83% of the portfolio. Baker Brothe...

2023-07-30 05:55:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron International Growth Fund outperformed its benchmark index and the all-cap growt...

2023-07-27 18:57:01 ET argenx SE (ARGX) Q2 2023 Earnings Conference Call July 27, 2023, 08:30 ET Company Participants Beth DelGiacco - VP and Global Head, Corporate Communications & IR Tim Van Hauwermeiren - CEO & Executive Director Karl Gubitz - CFO ...

$269 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales VYVGART® Hytrulo now available in the U.S. with first vials shipped in July Global VYVGART expansion continued with commercial launch in Italy and distribution agreement with Handok...

2023-07-26 07:00:00 ET Summary Baron Health Care Fund invests in companies engaged in the research, development, production, sale, delivery, or distribution of products and services related to the healthcare industry. In the quarter ended June 30, 2023, Baron Health Care Fund adva...

Regulated information – Inside i nformation July 24, 2023, 4 : 30 PM ET July 24, 2023, 10 : 30 PM CET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company comm...

2023-07-21 13:01:14 ET Summary argenx has released preliminary results from the ADHERE trial, which tested VYVGART Hytrulo on adults with chronic inflammatory demyelinating polyneuropathy (CIDP), where the trial results were positive. The trial, involving 322 adult patients, found...